Amneal Pharmaceuticals, Inc.
NASDAQ:AMRXDrug Manufacturers - Specialty & Generic
-$0.15 today
- Market cap
- $7.62B
- Beta
- 1.32
- P/E (TTM)
- 43.4
- EPS (TTM)
- $0.37
Volume 1.91M
Average 1.75M
AMRX Operating Cash Flow
Cash generated by the company's core business operations during the period.
Amneal Pharmaceuticals, Inc.NASDAQ: AMRX
Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Operating cash flow turns negative
Q2 FY2026 operating cash flow was -$19.26M, compared with $83.82M a year earlier. Trailing-twelve-month operating cash flow was $200.78M. Over 3 fiscal years it compounded at +73.5% a year.
Context
- Operating cash flow amounted to 11.3% of revenue in FY2025, up 0.7 pp from a year earlier.
- Operating cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly operating cash flow holds near -$19.26M or moves back toward the trailing-twelve-month quarterly average of $50.19M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 339.99M USD
- Year-over-year change
- +15.2%
- 4-year CAGR
- +8.9%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 339.99M | +15.2% |
| FY2024 | 2024-12-31 | 295.1M | -14.6% |
| FY2023 | 2023-12-31 | 345.58M | +430.8% |
| FY2022 | 2022-12-31 | 65.1M | -73.1% |
| FY2021 | 2021-12-31 | 241.82M | — |
Operating Cash Flow vs competitors
How AMRX compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -42.8% is the 8th highest of 11, against a peer median of +0.2%.
- Operating cash flow amounts to 6.4% of revenue for AMRX, versus a peer median of 13.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹30.11B INR | -48.8% | -1.3% | 9.1% | |
| LTM Jun 2026 | $2.33B USD | +12.9% | -8.3% | 15.8% | |
| LTM Jun 2026 | $1.9B USD | +36.5% | +1.2% | 11.0% | |
| LTM Jun 2026 | $1.8B USD | +19.7% | — | 16.6% | |
| LTM Jun 2026 | $251.8M USD | -31.2% | -8.1% | 6.1% | |
| LTM Mar 2026 | $208.61M USD | +158.4% | — | 22.6% | |
| LTM Jun 2026 | $200.78M USD | -42.8% | +73.5% | 6.4% | |
| LTM Mar 2026 | $168.88M USD | -12.6% | +20.5% | 23.4% | |
| LTM Mar 2026 | $148M USD | +34.4% | — | 21.9% | |
INDVIndivior Pharmaceuticals Inc | LTM Jun 2026 | $40M USD | -117.4% | +89.0% | 3.0% |
| LTM Mar 2026 | $1.42M USD | -73.8% | -16.4% | 3.4% | |
| Peer median (excluding AMRX) | — | +0.2% | -1.3% | 13.4% | |
Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 10.62M | (254.79M) | (48.72M) | (73.88M) | 72.06M |
| Depreciation & Amortization | 233.41M | 240.18M | 229.4M | 236.19M | 223.57M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 31.85M | 26.82M | 27.77M | 31.95M |
| Change in Working Capital | (133.59M) | (59.95M) | (47.19M) | (4.07M) | (204.52M) |
| Accounts Receivables | (16.31M) | (79.07M) | 125.8M | (162.16M) | (120.57M) |
| Inventory | (49.02M) | (102.4M) | (126.18M) | (130.53M) | (87.03M) |
| Accounts Payables | (43.93M) | 109.57M | (94.45M) | 235.14M | 21.32M |
| Other Working Capital | (24.34M) | 11.95M | 47.64M | 53.48M | (18.23M) |
| Other Non-Cash Items | 131.38M | 107.81M | 185.26M | 109.08M | 216.93M |
| Operating Cash Flow | 241.82M | 65.1M | 345.58M | 295.1M | 339.99M |
| Capital Expenditures | (47.73M) | (90.6M) | (69.19M) | (74.99M) | (70.06M) |
| Acquisitions (Net) | (141.54M) | (84.71M) | 0 | 11.99M | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (3.21M) | (40.8M) | (22.39M) | (14.65M) | (42.2M) |
| Investing Cash Flow | (194.18M) | (174.31M) | (69.19M) | (63M) | (112.26M) |
| Debt Repayment | (79.18M) | (38.27M) | 22.65M | (185.12M) | 26.27M |
| Common Stock Issued | 853K | 0 | 0 | 0 | 1.96M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (59.8M) | (68.35M) | (235.23M) | (26.67M) | (59.76M) |
| Financing Cash Flow | (138.12M) | (106.62M) | (212.57M) | (211.79M) | (31.53M) |
| Effect of Forex Changes | 102K | (5.68M) | 65K | (999K) | (1.68M) |
| Net Change in Cash | (90.38M) | (221.51M) | 63.88M | 19.31M | 194.52M |
| Free Cash Flow | 194.09M | (25.5M) | 276.39M | 220.11M | 269.93M |
Amneal Pharmaceuticals, Inc.
NASDAQ:AMRX
Intrinsic Alpha fair value
Locked
Current Price
$21.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.